Abstract
α-Synuclein (a-syn) oligomers and fibrils are behind neurodegeneration in Parkinson's disease (PD), but therapeutically targeting them is challenging. Amphipathic and cationic helical peptides inhibit amyloid formation and suppress neurotoxicity by selectively binding the solvent-accessible regions in these toxic species. Can endogenous peptides, like LL-37, constitute a new therapeutic paradigm in PD?
Author supplied keywords
Cite
CITATION STYLE
APA
Santos, J., Pallarès, I., & Ventura, S. (2022, August 1). Is a cure for Parkinson’s disease hiding inside us? Trends in Biochemical Sciences. Elsevier Ltd. https://doi.org/10.1016/j.tibs.2022.02.001
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free